Vijay Suhag, M.D.
Vijay S. Suhag, MD, is a hematologist-oncologist at the Sutter Roseville Cancer Center. He is board certified in internal medicine and is a National Cancer Institute-designated cancer researcher.
Dr. Suhag investigates novel therapies for hematological malignancies and solid tumor cancers. He participates in cooperative group cancer clinical trials testing new immunotherapies and targeted therapies.
Dr. Suhag obtained an MD from University College of Medical Sciences in New Delhi, India. He completed residency training in internal medicine at Drexel University College of Medicine in Philadelphia, PA, and a fellowship in hematology and medical oncology at Washington Hospital Center in Washington, DC.
Clinical trials
Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations
Status: Open to Enrollment
- Clinical trial
Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer
Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations
Status: Coming Soon
- Clinical trial
Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Status: Open to Enrollment